GlassScriptPhysician profile
David L Palombo
NPI 1336105972
$5,658.69
in general payments reported to CMS, 2019-2025
36 companies · $1,669 in 2025
The $1,669 reported for 2025 was more than what 96% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.74 · 2020: $110 · 2021: $322 · 2022: $502 · 2023: $1,098 · 2024: $1,890 · 2025: $1,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,658.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $1,086.23 | 2019-2025 | Provenge |
| Sumitomo Pharma America, INC. | $616.96 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $548.08 | 2021-2025 | |
| Endo USA, INC. | $438.14 | 2024-2025 | Xiaflex, Aveed |
| Urogen Pharma, INC. | $432.60 | 2020-2025 | Jelmyto |
| Blue Earth Diagnostics | $324.57 | 2021-2025 | Posluma |
| Janssen Biotech, INC. | $256.88 | 2022-2025 | Erleada |
| Novartis Pharmaceuticals Corporation | $249.85 | 2023-2025 | |
| Endo Pharmaceuticals INC. | $229.06 | 2021-2024 | Xiaflex, Aveed |
| Progenics Pharmaceuticals, INC. | $219.18 | 2023-2025 | Pylarify |
| Merck Sharp & Dohme LLC | $179.65 | 2020-2025 | Keytruda, Welireg, Lynparza |
| Bioprotect Medical, INC. | $126.84 | 2024 | Bioprotect Balloon Implant System |
| Amgen INC. | $115.43 | 2020-2021 | |
| Antares Pharma, INC. | $93.45 | 2020-2025 | Xyosted, Tlando, Nocdurna |
| Abbvie INC. | $90.31 | 2023-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $78.27 | 2024-2025 | Xt Cdx |
| Urovant Sciences INC | $72.36 | 2022 | |
| Procept Biorobotics Corporation | $66.34 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Ethicon US, LLC | $59.17 | 2022-2024 | Echelon Flex, Stratafix, Endopath Xcel |
| Accord Healthcare, INC. | $34.83 | 2023-2025 | |
| Neotract INC. | $33.38 | 2019 | |
| Teleflex LLC | $32.75 | 2021-2025 | Barrigel |
| Cardinal Health 414 LLC | $30.19 | 2025 | |
| Sun Pharmaceutical Industries INC. | $28.06 | 2023 | Yonsa |
| Ferring Pharmaceuticals INC. | $24.92 | 2025 | Adstiladrin |
| Ambu INC. | $23.98 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $22.75 | 2022 | |
| Cycle Pharmaceuticals INC | $22.30 | 2024 | Tiopronin |
| Azurity Pharmaceuticals, INC. | $22.04 | 2025 | Azmiro |
| Astellas Pharma US INC | $19.16 | 2025 | Xtandi |
| Genzyme Corporation | $15.64 | 2022 | |
| Foundation Medicine, INC. | $14.49 | 2019 | |
| Immunitybio, INC. | $14.05 | 2025 | |
| Myovant Sciences INC. | $13.14 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.06 | 2023 | Seglentis |
| Clarus Therapeutics INC. | $10.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Palombo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.